Portal:CPTAC/Hallmark/Therapeutics

Revision as of 18:08, 10 October 2019 by Khanspers (Talk | contribs)

Pathway:WP3672 LncRNA-mediated mechanisms of therapeutic resistance
Pathway:WP3640 Imatinib and Chronic Myeloid Leukemia
Pathway:WP3614 Photodynamic therapy-induced HIF-1 survival signaling
Pathway:WP3617 Photodynamic therapy-induced NF-kB survival signaling
Pathway:WP3879 4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression
Pathway:WP1601 Fluoropyrimidine Activity
Pathway:WP3 Phytochemical activity on NRF2 transcriptional activation
Pathway:WP4357 NRF2-ARE regulation
Pathway:WP4301 Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells
Pathway:WP3844 PI3K-AKT-mTOR signaling pathway and therapeutic opportunities
Pathway:WP3593 MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma
Pathway:WP4585 Cancer immunotherapy by PD-1 blockade
Pathway:WP4582 Cancer immunotherapy by CTLA4 blockade
Pathway:WP4559 Interactions between immune cells and microRNAs in tumor microenvironment
Pathway:WP4560 MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement